PubMed Health⌕ Search

PubMed · 11088550

Kramers problem for a polymer in a double well

Abstract

We consider a long chain molecule, initially confined to the metastable side of a biased double well potential. It can escape from this side to the other by the motion of its N segments across the barrier. We assume that the length of the molecule is much larger than the width w of the barrier. The width w is taken to be sufficiently large that a continuum description is applicable to even the portion over the barrier. We use the Rouse model and analyze the mechanism of crossing the barrier. There can be two dominant mechanisms: end crossing and hairpin crossing. We find the free energy of activation for the hairpin crossing to be two times that for end crossing. The pre-exponential factor for hairpin crossing is proportional to N, while it is independent of N for end crossing. In both cases, the activation energy has a square root dependence on the temperature T, leading to a non-Arrhenius form for the rate. We also show that there is a special time dependent solution of the model, which corresponds to a kink in the chain, confined to the region of the barrier. The movement of the polymer from one side to the other is equivalent to the motion of the kink on the chain in the reverse direction. If there is no free energy difference between the two sides of the barrier, then the kink moves by diffusion and the time of crossing t(cross) approximately N(2)/T(3/2). If there is a free energy difference, then the kink moves with a nonzero velocity from the lower free energy side to the other, leading to t(cross) approximately N/sqrt[T]. We also discuss the applicability of the mechanism to the recent experiments of Kasianowicz [Proc. Natl. Acad. Sci. USA 93, 13 770 (1996)], where DNA molecules were driven through a nanopore by the application of an electric field. The prediction that t(cross) approximately N is in agreement with these experiments. Our results are in agreement with the recent experimental observations of Han, Turner, and Craighead [Phys. Rev. Lett. 83, 1688 (1999)]. We also consider the translocation of hydrophilic polypeptides across hydrophobic pores, a process that is quite common in biological systems. Biological systems accomplish this by having a hydrophobic signal sequence at the end that goes in first. We find that for such a molecule, the transition state resembles a hook, and this is in agreement with presently accepted view in cell biology.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

KL Sebastian, AK Paul. 2000. Kramers problem for a polymer in a double well. https://doi.org/10.1103/physreve.62.927

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗